Biotech RadarJobs updated

COMPANY

TRU Diagnostics Inc.

HQ: Lexington, KY source · trudiagnostic.com ↗ · Southeast

Clinical Phase 3

Location: Lexington, KY · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Aging Depression Post Traumatic Stress Disorder Aging Well Sleep Covid19 Ketamine SARS-CoV-2 mRNA vaccine

11Trials (company is sponsor)1NIH grants

Timeline

  1. Trial start Phase 2: Targeting the Nine Hallmarks of Aging on DNA Methylation source ↗
  2. Trial start Phase 2: Ketamine and Epigenetic Aging source ↗
  3. Trial start Phase 2/Phase 3: A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging source ↗
  4. Trial start Phase 2: The Impact of a Human Breast Milk Supplement on Epigenetic and Cellular Markers source ↗
  5. Trial start Phase 2: Electromagnetic Field Protection Device Use Impact in Healthy Volunteers source ↗
  6. Trial start Not phased (device or behavioral study): Clinical Efficacy of a Supplement on Sleep Quality source ↗
  7. Trial start Phase 2: AC-11 Supplement and Biological Aging source ↗
  8. Trial start Phase 2: Safety & Efficacy of Extended Longevity Protocol source ↗
  9. Trial start Phase 2: The Impact of a Fast Diet and Calorie Mimetic Supplements on Epigenetic Aging source ↗
  10. Trial start —: Methylation Effects of COV-19 Infection and Vaccinations source ↗
  11. Trial start Phase 2: Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging source ↗

Clinical trials (lead sponsor) 11

RecordTitlePhaseStatusStartPrimary completion
NCT05297019A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic AgingPhase 2/Phase 3Unknown status (ClinicalTrials.gov)Mar 1, 2022Apr 30, 2023 (estimated)
NCT05535608Targeting the Nine Hallmarks of Aging on DNA MethylationPhase 2Unknown status (ClinicalTrials.gov)Aug 15, 2022Dec 31, 2023 (estimated)
NCT05297097The Impact of a Human Breast Milk Supplement on Epigenetic and Cellular MarkersPhase 2Unknown status (ClinicalTrials.gov)Mar 1, 2022Dec 1, 2022 (estimated)
NCT05294835Ketamine and Epigenetic AgingPhase 2Unknown status (ClinicalTrials.gov)Apr 1, 2022Dec 31, 2022 (estimated)
NCT05296993Safety & Efficacy of Extended Longevity ProtocolPhase 2Unknown status (ClinicalTrials.gov)May 25, 20212022-12 (estimated)
NCT05310123AC-11 Supplement and Biological AgingPhase 2Unknown status (ClinicalTrials.gov)May 26, 20212022-10 (estimated)
NCT05001646Electromagnetic Field Protection Device Use Impact in Healthy VolunteersPhase 2Unknown status (ClinicalTrials.gov)2022-032023-01 (estimated)
NCT04988542Clinical Efficacy of a Supplement on Sleep QualityNot phased (device or behavioral study)Unknown status (ClinicalTrials.gov)Aug 30, 20212021-12 (estimated)
NCT04946383Safety and Effectivness of Quercetin & Dasatinib on Epigenetic AgingPhase 2Unknown status (ClinicalTrials.gov)Dec 16, 2020Dec 31, 2021 (estimated)
NCT04962464The Impact of a Fast Diet and Calorie Mimetic Supplements on Epigenetic AgingPhase 2Unknown status (ClinicalTrials.gov)Mar 10, 20212022-03 (estimated)
NCT04939155Methylation Effects of COV-19 Infection and VaccinationsNot listedUnknown status (ClinicalTrials.gov)Mar 10, 2021Oct 1, 2021 (estimated)

NIH awards 1

Annual award amounts. Total $321K.

Feedback